| Unknown | Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 an NCT03185494 | Chinese PLA General Hospital | Phase 1 / Phase 2 |
| Completed | Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 an NCT03097770 | Chinese PLA General Hospital | Phase 1 / Phase 2 |
| Withdrawn | Rituximab, Romidepsin, and Lenalidomide in Treating Patients With Recurrent or Refractory B-cell Non-Hodgkin L NCT02281279 | Mayo Clinic | Phase 1 / Phase 2 |
| Unknown | Anti-CD22 CAR-T Therapy for CD19-refractory or Resistant Lymphoma Patients NCT02721407 | Xinqiao Hospital of Chongqing | Phase 1 |
| Unknown | Competitive Transfer of αCD19-TCRz-CD28 and αCD19-TCRz-CD137 CAR-T Cells for B-cell Leukemia/Lymphoma NCT02685670 | The Second Affiliated Hospital of Henan University of Traditional Chinese Medicine | Phase 1 / Phase 2 |
| Unknown | Memory-enriched CAR-T Cells Immunotherapy for B Cell Lymphoma NCT02652910 | Xinqiao Hospital of Chongqing | Phase 1 / Phase 2 |
| Completed | Selinexor and Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Aggre NCT02303392 | Jennifer Woyach | Phase 1 |
| Withdrawn | Genetically Modified Peripheral Blood Stem Cell Transplant in Treating Patients With HIV-Associated Non-Hodgki NCT01769911 | Fred Hutchinson Cancer Center | N/A |
| Terminated | CPI-613, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non NCT02168907 | Wake Forest University Health Sciences | Phase 1 |
| Completed | Everolimus and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory Hematologic Cancer NCT02240719 | University of California, Davis | Phase 1 |
| Terminated | Ibrutinib in Treating Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma in Patients With HIV Infection NCT02109224 | National Cancer Institute (NCI) | Phase 1 |
| Active Not Recruiting | Rituxan/Bendamustine/PCI-32765 in Relapsed DLBCL, MCL, or Indolent Non-Hodgkin's Lymphoma NCT01479842 | Kami Maddocks, MD | Phase 1 |
| Completed | Dose Monitoring of Busulfan and Combination Chemotherapy in Hodgkin or Non-Hodgkin Lymphoma Undergoing Stem Ce NCT01959477 | Case Comprehensive Cancer Center | EARLY_Phase 1 |
| Withdrawn | Single or Double Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Hematologic Maligna NCT01652014 | University of Medicine and Dentistry of New Jersey | Phase 2 |
| Completed | MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma NCT01748721 | Morphotek | Phase 1 |
| Active Not Recruiting | Genetically Modified T-cell Infusion Following Peripheral Blood Stem Cell Transplant in Treating Patients With NCT01815749 | City of Hope Medical Center | Phase 1 |
| Completed | Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hemato NCT01789255 | National Cancer Institute (NCI) | Phase 2 |
| Terminated | Alisertib With and Without Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymph NCT01812005 | Ohio State University Comprehensive Cancer Center | Phase 2 |
| Completed | Pomalidomide and Dexamethasone in Treating Patients With Relapsed or Refractory Primary Central Nervous System NCT01722305 | Mayo Clinic | Phase 1 |
| Completed | Donor T Cells After Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies NCT01839916 | University of Chicago | Phase 2 |
| Unknown | Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by CART19 NCT01864889 | Chinese PLA General Hospital | N/A |
| Terminated | Ipilimumab and Local Radiation for Selected Solid Tumors NCT01769222 | Stanford University | Phase 1 |
| Unknown | Genetically Engineered Lymphocyte Therapy in Treating Patients With Lymphoma That is Resistant or Refractory t NCT01735604 | Chinese PLA General Hospital | Phase 1 / Phase 2 |
| Completed | Buparlisib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma NCT01719250 | Mayo Clinic | EARLY_Phase 1 |
| Completed | Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing NCT01588015 | City of Hope Medical Center | Phase 1 |
| Completed | Belinostat and Yttrium Y 90 Ibritumomab Tiuxetan in Patients W/Relapsed Aggressive B-Cell NHL NCT01686165 | University of Arizona | Phase 2 |
| Withdrawn | Mechanical Stimulation in Preventing Bone Density Loss in Patients Undergoing Donor Stem Cell Transplant NCT01558778 | Roswell Park Cancer Institute | N/A |
| Terminated | Lenalidomide With or Without Rituximab in Treating Patients With Progressive or Relapsed Chronic Lymphocytic L NCT01419795 | Fred Hutchinson Cancer Center | Phase 2 |
| Completed | CD19 CAR T Cells for B Cell Malignancies After Allogeneic Transplant NCT01475058 | Fred Hutchinson Cancer Center | Phase 1 / Phase 2 |
| Completed | Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem NCT01529827 | Roswell Park Cancer Institute | Phase 2 |
| Completed | Donor Peripheral Stem Cell Transplant in Treating Patients With Hematolymphoid Malignancies NCT01523223 | Robert Lowsky | Phase 1 |
| Terminated | High-Dose Y-90-Ibritumomab Tiuxetan Added to Reduced-Intensity Allogeneic Stem Cell Transplant Regimen for Rel NCT01434472 | Fred Hutchinson Cancer Center | Phase 2 |
| Terminated | Ofatumumab and Bortezomib in Subjects With Relapsed CD20+Diffuse Large B Cell, Follicular, or Mantle Cell Lymp NCT01397591 | OHSU Knight Cancer Institute | Phase 2 |
| Terminated | Etoposide, Filgrastim, and Plerixafor in Improving Stem Cell Mobilization in Treating Patients With Non-Hodgki NCT01408043 | Case Comprehensive Cancer Center | N/A |
| Completed | Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Trans NCT01427881 | Fred Hutchinson Cancer Center | Phase 2 |
| Completed | Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma NCT01326702 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Completed | Bortezomib and Filgrastim to Promote Stem Cell Mobilization in Patients With Non-Hodgkin Lymphoma or Multiple NCT02037256 | Barbara Ann Karmanos Cancer Institute | N/A |
| Completed | Methoxyamine and Fludarabine Phosphate in Treating Patients With Relapsed or Refractory Hematologic Malignanci NCT01658319 | Case Comprehensive Cancer Center | Phase 1 |
| Completed | Panobinostat in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma NCT01261247 | Mayo Clinic | Phase 2 |
| Completed | Everolimus and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma NCT01075321 | Mayo Clinic | Phase 1 / Phase 2 |
| Completed | Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic Malignancies NCT01273766 | Wake Forest University Health Sciences | Phase 2 |
| Terminated | Selumetinib in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma NCT01278615 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic NCT01199562 | City of Hope Medical Center | — |
| Completed | Study of Akt Inhibitor MK2206 in Patients With Relapsed Lymphoma NCT01258998 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Palifermin in Preventing Chronic Graft-Versus-Host Disease in Patients Who Have Undergone Donor Stem Cell Tran NCT01233921 | Martin, Paul | N/A |
| Completed | Bendamustine Hydrochloride, Rituximab, Etoposide, and Carboplatin in Treating Patients With Relapsed or Refrac NCT01165112 | University of Washington | Phase 1 / Phase 2 |
| Completed | Bendamustine Hydrochloride, Etoposide, Dexamethasone, and Filgrastim For Peripheral Blood Stem Cell Mobilizati NCT01110135 | University of Washington | Phase 2 |
| Terminated | Deferasirox for Treating Patients Who Have Undergone Allogeneic Stem Cell Transplant and Have Iron Overload NCT01159067 | City of Hope Medical Center | Phase 2 |
| Completed | RO4929097 and Capecitabine in Treating Patients With Refractory Solid Tumors NCT01158274 | National Cancer Institute (NCI) | Phase 1 |
| Terminated | Plerixafor and Filgrastim For Mobilization of Donor Peripheral Blood Stem Cells Before A Donor Peripheral Bloo NCT01076270 | Fred Hutchinson Cancer Center | N/A |
| Completed | AR-42 in Treating Patients With Advanced or Relapsed Multiple Myeloma, Chronic Lymphocytic Leukemia, or Lympho NCT01129193 | Amir Mortazavi | Phase 1 |
| Terminated | Vorinostat and Lenalidomide in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin L NCT01116154 | City of Hope Medical Center | Phase 1 |
| Completed | CART19 to Treat B-Cell Leukemia or Lymphoma That Are Resistant or Refractory to Chemotherapy NCT01029366 | University of Pennsylvania | Phase 1 |
| Terminated | Lenalidomide And Rituximab as Maintenance Therapy in Treating Patients With B-Cell Non-Hodgkin Lymphoma NCT01045928 | Case Comprehensive Cancer Center | Phase 1 |
| Terminated | Rituximab in Preventing Acute Graft-Versus-Host Disease in a Donor Stem Cell Transplant for Hematologic Cancer NCT01044745 | University of Nebraska | Phase 2 |
| Completed | Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy NCT00890747 | National Cancer Institute (NCI) | Phase 1 |
| Completed | FAU in Treating Patients With Advanced Solid Tumors or Lymphoma NCT00769288 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Gossypol, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be NCT00891072 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Panobinostat and Everolimus in Treating Patients With Recurrent Multiple Myeloma, Non-Hodgkin Lymphoma, or Hod NCT00918333 | Mayo Clinic | Phase 1 / Phase 2 |
| Completed | Rituximab in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant for Relapsed or Refracto NCT00867529 | Fred Hutchinson Cancer Center | Phase 2 |
| Completed | Fludarabine Phosphate, Melphalan, Total-Body Irradiation, Donor Stem Cell Transplant in Treating Patients With NCT00856388 | Roswell Park Cancer Institute | N/A |
| Completed | Dasatinib in Treating Patients With Solid Tumors or Lymphomas That Are Metastatic or Cannot Be Removed By Surg NCT00608361 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Ondansetron in Preventing Nausea and Vomiting in Patients Undergoing Stem Cell Transplant NCT00795769 | Fred Hutchinson Cancer Center | Phase 2 |
| Completed | Internet-Based Program With or Without Telephone-Based Problem-Solving Training in Helping Long-Term Survivors NCT00799461 | Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium | Phase 3 |
| Terminated | Obatoclax and Bortezomib in Treating Patients With Aggressive Relapsed or Recurrent Non-Hodgkin Lymphoma NCT00538187 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Vorinostat, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory NCT00601718 | University of Washington | Phase 1 / Phase 2 |
| Completed | Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies NCT01093586 | Case Comprehensive Cancer Center | Phase 2 |
| Completed | Vorinostat in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphoma and Liver Dysfunction NCT00499811 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Bevacizumab and Cediranib Maleate in Treating Patients With Metastatic or Unresectable Solid Tumor, Lymphoma, NCT00458731 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Beclomethasone Dipropionate in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem NCT00489203 | Fred Hutchinson Cancer Center | Phase 2 |
| Completed | Sunitinib in Treating Patients With Relapsed or Refractory Diffuse or Mediastinal Large B-Cell Lymphoma NCT00392496 | National Cancer Institute (NCI) | Phase 2 |
| Terminated | FR901228 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma NCT00383565 | National Cancer Institute (NCI) | Phase 2 |
| Completed | High-Dose Chemotherapy With or Without Total-Body Irradiation Followed by Autologous Stem Cell Transplant in T NCT00536601 | Roswell Park Cancer Institute | N/A |
| Completed | 3-AP and Gemcitabine in Treating Patients With Advanced Solid Tumors or Lymphoma NCT00293345 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Lithium Carbonate in Treating Patients With Acute Intestinal Graft-Versus-Host-Disease (GVHD) After Donor Stem NCT00408681 | Fred Hutchinson Cancer Center | N/A |
| Terminated | PXD101 and 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Metastatic or Unresectable Solid NCT00354185 | National Cancer Institute (NCI) | Phase 1 |
| Completed | A Pilot Study to Evaluate the Co-Infusion of Ex Vivo Expanded Cord Blood Cells With an Unmanipulated Cord Bloo NCT00343798 | Fred Hutchinson Cancer Center | Phase 1 |
| Completed | Decitabine With or Without Valproic Acid in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lympho NCT00109824 | National Cancer Institute (NCI) | Phase 1 |
| Completed | PXD101 and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas NCT00348985 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Vorinostat and Decitabine in Treating Patients With Advanced Solid Tumors or Relapsed or Refractory Non-Hodgki NCT00275080 | National Cancer Institute (NCI) | Phase 1 |
| Completed | PXD101 in Treating Patients With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma NCT00303953 | National Cancer Institute (NCI) | Phase 2 |
| Terminated | Flavopiridol in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma NCT00112723 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Terminated | Fenretinide and Rituximab in Treating Patients With B-Cell Non-Hodgkin Lymphoma NCT00288067 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Completed | Sorafenib in Treating Patients With Recurrent Non-Hodgkin's Lymphoma NCT00278382 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Sorafenib Tosylate in Treating Patients With Recurrent Aggressive Non-Hodgkin's Lymphoma NCT00131937 | National Cancer Institute (NCI) | Phase 2 |
| Terminated | 17-N-Allylamino-17-Demethoxygeldanamycin and Bortezomib in Treating Patients With Relapsed or Refractory Hemat NCT00103272 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofe NCT00118352 | Fred Hutchinson Cancer Center | Phase 2 |
| Completed | Iodine I 131 Tositumomab and Fludarabine Phosphate in Treating Older Patients Who Are Undergoing an Autologous NCT00110071 | Fred Hutchinson Cancer Center | Phase 1 |
| Terminated | Tanespimycin and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas NCT00096005 | National Cancer Institute (NCI) | Phase 1 |
| Terminated | SB-715992 in Treating Patients With Metastatic or Unresectable Solid Tumors or Hodgkin's or Non-Hodgkin's Lymp NCT00101244 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Tacrolimus and Mycophenolate Mofetil With or Without Sirolimus in Preventing Acute Graft-Versus-Host Disease i NCT00105001 | Fred Hutchinson Cancer Center | Phase 2 |
| Completed | Sorafenib in Treating Patients With Metastatic or Unresectable Solid Tumors, Multiple Myeloma, or Non-Hodgkin' NCT00118170 | National Cancer Institute (NCI) | Phase 1 |
| Completed | MS-275 and Isotretinoin in Treating Patients With Metastatic or Advanced Solid Tumors or Lymphomas NCT00098891 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Agatolimod Sodium, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Recurrent or Ref NCT00438880 | Mayo Clinic | Phase 1 / Phase 2 |
| Completed | 17-DMAG in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphomas NCT00089271 | National Cancer Institute (NCI) | Phase 1 |
| Terminated | MDX-010 in Treating Patients With Recurrent or Refractory Lymphoma NCT00089076 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Completed | Yttrium Y 90 Ibritumomab Tiuxetan, Fludarabine, Radiation Therapy, and Donor Stem Cell Transplant in Treating NCT00119392 | Fred Hutchinson Cancer Center | Phase 2 |
| Completed | Oblimersen, Rituximab and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Aggressive NCT00086944 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Terminated | CCI-779 in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia NCT00086840 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone To NCT00089011 | Fred Hutchinson Cancer Center | Phase 2 |
| Completed | Bortezomib and Flavopiridol in Treating Patients With Recurrent or Refractory Indolent B-Cell Neoplasms NCT00082784 | National Cancer Institute (NCI) | Phase 1 |
| Completed | CCI-779 in Treating Patients With Recurrent or Refractory B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic NCT00290472 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Cilengitide (EMD 121974) in Treating Patients With Advanced Solid Tumors or Lymphoma NCT00077155 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Mali NCT00078858 | Fred Hutchinson Cancer Center | Phase 1 / Phase 2 |
| Completed | Gemcitabine Hydrochloride, Carboplatin, Dexamethasone, and Rituximab in Treating Patients With Previously Trea NCT00072514 | Fred Hutchinson Cancer Center | Phase 2 |
| Completed | Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Post-Transplant Lymphoproliferative NCT00064246 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Completed | Ipilimumab After Allogeneic Stem Cell Transplant in Treating Patients With Persistent or Progressive Cancer NCT00060372 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Bryostatin 1 Plus Vincristine in Treating Patients With Progressive or Relapsed Non-Hodgkin's Lymphoma After B NCT00058305 | National Cancer Institute (NCI) | Phase 2 |
| Terminated | Oblimersen and Gemcitabine in Treating Patients With Advanced Solid Tumor or Lymphoma NCT00060112 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Ixabepilone in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma NCT00058019 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Oblimersen Sodium and Rituximab in Treating Patients With Recurrent B-cell Non-Hodgkin Lymphoma NCT00054639 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Bortezomib in Treating Patients With Advanced Cancer and Kidney Dysfunction NCT00054483 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Haploidentical Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancer NCT00049504 | Fred Hutchinson Cancer Center | Phase 2 |
| Completed | Alemtuzumab, Fludarabine Phosphate, and Low-Dose Total Body Irradiation Before Donor Stem Cell Transplantation NCT00040846 | Fred Hutchinson Cancer Center | Phase 2 |
| Completed | Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver Dysfunction NCT00025415 | National Cancer Institute (NCI) | Phase 1 |
| Completed | S0108 Bevacizumab in Treating Patients With Non-Hodgkin's Lymphoma NCT00016094 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Monoclonal Antibody Therapy and Peripheral Stem Cell Transplant in Treating Patients With Non-Hodgkin's Lympho NCT00017381 | National Cancer Institute (NCI) | EARLY_Phase 1 |
| Completed | Fludarabine Phosphate and Total-Body Radiation Followed by Donor Peripheral Blood Stem Cell Transplant and Imm NCT00014235 | Fred Hutchinson Cancer Center | N/A |
| Completed | Rituximab Plus Interleukin-2 in Treating Patients With Hematologic Cancer NCT00010192 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Oxaliplatin in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma NCT00006473 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporin NCT00006251 | Fred Hutchinson Cancer Center | Phase 1 / Phase 2 |
| Completed | 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Advanced Epithelial Cancer, Malignant Lymph NCT00004241 | National Cancer Institute (NCI) | Phase 1 |
| Terminated | Monoclonal Antibody Therapy Before Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymph NCT01678443 | Fred Hutchinson Cancer Center | Phase 1 |
| Terminated | Geldanamycin Analogue in Treating Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma NCT00019708 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Iodine I 131 Tositumomab, Etoposide and Cyclophosphamide Followed by Autologous Stem Cell Transplant in Treati NCT00073918 | Fred Hutchinson Cancer Center | Phase 2 |
| Completed | Genetic Testing Plus Irinotecan in Treating Patients With Solid Tumors or Lymphoma NCT00003970 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Bryostatin and Vincristine in B-Cell Malignancies NCT00003166 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Interleukin-12 in Treating Patients With Previously Treated Non-Hodgkin's Lymphoma or Hodgkin's Disease NCT00003210 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Low-Dose Total Body Irradiation and Donor Peripheral Blood Stem Cell Transplant Followed by Donor Lymphocyte I NCT00003196 | Fred Hutchinson Cancer Center | N/A |
| Completed | Interleukin-2 or Observation Following Radiation Therapy, Combination Chemotherapy, and Peripheral Stem Cell T NCT00002649 | National Cancer Institute (NCI) | Phase 3 |
| Completed | High-Dose Busulfan and High-Dose Cyclophosphamide Followed By Donor Bone Marrow Transplant in Treating Patient NCT01177371 | Case Comprehensive Cancer Center | Phase 2 |